Compare CYD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | EYPT |
|---|---|---|
| Founded | 1951 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1994 | 2005 |
| Metric | CYD | EYPT |
|---|---|---|
| Price | $35.73 | $16.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.60 |
| AVG Volume (30 Days) | 161.6K | ★ 1.1M |
| Earning Date | 08-08-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 40.10 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $3,159,401,156.00 | $42,339,000.00 |
| Revenue This Year | $41.12 | N/A |
| Revenue Next Year | $6.93 | N/A |
| P/E Ratio | $21.64 | ★ N/A |
| Revenue Growth | ★ 17.99 | N/A |
| 52 Week Low | $8.61 | $3.91 |
| 52 Week High | $42.60 | $19.11 |
| Indicator | CYD | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 59.80 |
| Support Level | $34.54 | $15.97 |
| Resistance Level | $36.20 | $19.11 |
| Average True Range (ATR) | 1.14 | 0.96 |
| MACD | 0.11 | 0.10 |
| Stochastic Oscillator | 55.00 | 44.91 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.